Last Updated

30 Mar 2022

Malaria Vaccine R&D and Immunization - Lessons Learned & Considerations for Global Health Impact

Click on the image above to watch the video:

Global Vaccine and Immunization Research Forum (GVIRF): Malaria Vaccine R&D and Immunization

The first-generation malaria vaccine RTS,S/ASO1 is an important advance in combatting a difficult pathogen and illustrates critical obstacles facing the vaccine and immunization communities. Using RTS,S/AS01 as a case study, this webinar explored lessons learned and discussed vaccine R&D considerations for malaria and other diseases of global health importance prevalent in resource-limited settings.  

Webinar Topics (see Agenda)

  • The RTS,S/AS01 vaccine and lessons learned 
  • Future malaria R&D priorities and strategies
  • Vaccine development hurdles and challenges
  • Implementation and distribution considerations
  • Manufacturing and accessibility impediments
  • Safety and regulatory concerns 
  • Resources and global collaboration

About

The Global Vaccine and Immunization Research Forum (GVIRF) is a global meeting that brings together the entire vaccine and immunization research community and organized by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the Bill & Melinda Gates Foundation (BMGF), and the World Health Organization (WHO).